HEALTHCARE ECONOMICS PUBLICATIONS & ABSTRACTS
Healthcare Economics Data
Evidence / Healthcare Economics
Cost Effectiveness of MammaPrint in Brazil
The Breast 76 (2024) 103752 Author: Mansani et al.
Read MoreCost consequence model of MammaPrint in Germany
: Cost consequence model of the MammaPrintยฎ (70-gene signature) and 21-gene signature in Patients with primary HR+ HER2-, N1 early-stage breast cancer in Germany
Read MoreBudget impact analysis for the Health Care Package by using MammaPrint in Belgium
ย Publication: ESMO BREAST CANCER CONGRESS 2022 Authors De Lameillieure K (1), Van der Meijden C (1), Klinkhamer J (1) , Cusumano P (2). 1- Medical & Clinical Affairs, Agendia NV., Amsterdam, Netherlands, 2 - Breast Clinic, Centre Hospitalier Chrรฉtien, Liรจge, Belgium Background & Objective Gene expression profiling (GEP) tests, Read More
Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trial
PUBLICATION: European Journal of Cancer AUTHORS: Valesca P. Retel, Danalyn Byng, Sabine C. Linn, Katarzyna Jozwiak, Hendrik Koffijberg, Emiel J. Rutgers, Fatima Cardoso, Martine J. Piccart, Coralie Poncet, Laura J. van โt Veer, Wim H. van Harten. Abstract: The clinical utility of the 70-gene signature (MammaPrintยฎ) to guide chemotherapy Read More
Genomic Profile of Breast Cancer: Cost-Effectiveness Analysis from the Spanish National Healthcare System Perspective
PUBLICATION: Expert Rev Pharmacoecon Outcomes Res. 2014 Dec;14(6):889-99. doi: 10.1586/14737167.2014.957185. Epub 2014 Sep 12. AUTHORS: Seguรญ M.ร., Crespo C., Cortรฉs J., Lluch A., Brosa M., Becerra V., Chiavenna S.M., Gracia A. SUMMARY: A 70-gene signature showed a life expectancy of 23.55 years at lifetime. Life expectancy was lower for 21-gene Read More
Prospective Cost-Effectiveness Analysis of Genomic Profiling in Breast Cancer
PUBLICATION: European Journal of Cancer. December 2013, Volume 49, Issue 18, Pages 3773โ3779 AUTHORS: V.P. Retรจl, M.A. Jooreb, C.A. Drukker, J.M. Bueno-de-Mesquita, M. Knauer, H. van Tinteren, S.C. Linn, W.H. van Harten SUMMARY: The total health care costs per patient were โฌ26,786 for the 70-gene and โฌ29,187 for AO. The Read More
Multigene Assays and Molecular Markers in Breast Cancer: Systematic Review of Health Economic Analyses
PUBLICATION: Breast Cancer Res Treat. 2013 Jun;139(3):621-37. doi: 10.1007/s10549-013-2559-1. Epub 2013 May 31. AUTHORS: Rouzier R., Pronzato P., Chรฉreau E., Carlson J., Hunt B., Valentine W.J. SUMMARY: Systematic Review: The review identified 29 publications that reported evaluations of two assays: Oncotype DX(ยฎ) and MammaPrint. Studies of both tests provided evidence Read More